Home > Share Market > Stocks > Venus remedies > Financial Statements > VENUSREM Key Financial Ratios

Venus remedies Financial Statements

VENUSREM Ratio Analysis

  • Tabular Data
  • Graph
  • Consolidated
  • Standalone
Y/e 31 Mar Mar-2022 Mar-2021 Mar-2020 Mar-2018
Growth matrix (%)        
Revenue growth 9.22 61.50 (8.90) (6.90)
Op profit growth 15.50 31.70 3.41 (22)
EBIT growth (3.30) 170 78.80 (38)
Net profit growth (34) (718) (67) 79.70
Profitability ratios (%)        
OPM 10.40 9.81 12 10.60
EBIT margin 6.16 6.96 4.16 2.12
Net profit margin 6.80 11.30 (2.90) (8.20)
RoCE 7.86 7.51 2.27 1.13
RoNW 2.42 4.27 (0.70) (2)
RoA 2.17 3.04 (0.40) (1.10)
Per share ratios ()        
EPS 30.50 50 (8.10) --
Dividend per share -- -- -- --
Cash EPS 5.38 21.50 (34) (52)
Book value per share 330 324 262 293
Valuation ratios        
P/E 8.82 5.49 (2.80) --
P/CEPS 50 12.80 (0.70) (1.30)
P/B 0.82 0.85 0.09 0.22
EV/EBIDTA 5 4.89 5.34 9.20
Payout (%)        
Dividend payout -- -- -- --
Tax payout 11.90 52.60 (253) 11.50
Liquidity ratios        
Debtor days 21.50 20.90 41.90 46.30
Inventory days 74.90 86.90 150 137
Creditor days (43) (40) (41) (33)
Leverage ratios        
Interest coverage (77) (2.90) (1.10) (0.20)
Net debt / equity -- 0.05 0.68 0.84
Net debt / op. profit (0.10) 0.37 5.35 7.67
Cost breakup ()        
Material costs (64) (62) (51) (55)
Employee costs (8.70) (8.40) (14) (11)
Other costs (16) (20) (23) (24)

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000